When a Child’s Cancer Resists Treatment: The Potential of Immunotherapy

This encouraging presentation from pediatric hematologist-oncologist Michelle Hermiston, MD, PhD, director of UCSF’s pediatric immunotherapy program, focuses on relapsed acute lymphoblastic leukemia, the most common childhood cancer. Illuminating the physiology of harnessing the immune system to target cancer, she explains the benefits, risks and strategic use of CAR-T cell therapy, which has greatly improved the prognosis for kids in this population.

Created by

UCSF Pediatrics

Related Presenters

Michelle Hermiston, MD, PhD

Michelle Hermiston, MD, PhD

Pediatric hematologist-oncologist
Bone marrow transplant specialist
Director, Pediatric Immunotherapy Program

View full profile